Celldex Therapeutics (CLDX)
(Delayed Data from NSDQ)
$22.19 USD
+0.21 (0.96%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $22.21 +0.02 (0.09%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Dividend Yield (TTM)
Celldex Therapeutics, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
CLDX 22.19 +0.21(0.96%)
Will CLDX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CLDX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CLDX
scPharmaceuticals (SCPH) Soars 8.8%: Is Further Upside Left in the Stock?
Xenon Pharmaceuticals (XENE) Up 8.7% Since Last Earnings Report: Can It Continue?
CLDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Celldex Therapeutics (CLDX) Reports Q1 Loss, Lags Revenue Estimates
Cytokinetics (CYTK) Moves 5.4% Higher: Will This Strength Last?
Celldex Therapeutics (CLDX) Reports Q4 Loss, Lags Revenue Estimates
Other News for CLDX
Interesting CLDX Put And Call Options For September 19th
RBC downgrades Jasper Therapeutics on questions about briquilimab
Celldex Therapeutics’ Promising Phase 2 Study on Eosinophilic Esophagitis
Celldex’s Phase 3 Study on Barzolvolimab: A Potential Game-Changer for Chronic Urticaria
Celldex Therapeutics Advances Phase 2 Study on Barzolvolimab for Prurigo Nodularis